NeuroPace (NASDAQ:NPCE) Price Target Raised to $14.00

NeuroPace (NASDAQ:NPCE - Free Report) had its price objective boosted by JPMorgan Chase & Co. from $9.00 to $14.00 in a research note published on Tuesday morning,Benzinga reports. They currently have an overweight rating on the stock.

Separately, Wells Fargo & Company reduced their target price on NeuroPace from $15.00 to $13.00 and set an "overweight" rating for the company in a report on Wednesday, November 13th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $14.50.

NeuroPace Stock Up 0.4 %

NeuroPace stock traded up $0.05 during trading on Tuesday, reaching $11.52. The company had a trading volume of 103,674 shares, compared to its average volume of 95,690. The firm's 50-day simple moving average is $8.42 and its 200 day simple moving average is $7.59. The company has a debt-to-equity ratio of 6.03, a current ratio of 5.59 and a quick ratio of 4.77. NeuroPace has a 1-year low of $5.45 and a 1-year high of $18.15.

NeuroPace (NASDAQ:NPCE - Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.07. NeuroPace had a negative net margin of 36.74% and a negative return on equity of 205.41%. The business had revenue of $21.06 million for the quarter, compared to analyst estimates of $19.33 million. During the same quarter last year, the business earned ($0.28) earnings per share. Sell-side analysts forecast that NeuroPace will post -1 EPS for the current year.

Insiders Place Their Bets

In other news, major shareholder Ltd. Kck sold 4,910 shares of NeuroPace stock in a transaction on Monday, October 7th. The stock was sold at an average price of $6.66, for a total transaction of $32,700.60. Following the transaction, the insider now owns 5,540,104 shares in the company, valued at $36,897,092.64. The trade was a 0.09 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold 257,590 shares of company stock valued at $1,437,916 in the last ninety days. 22.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On NeuroPace

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Millennium Management LLC lifted its stake in shares of NeuroPace by 13.3% in the 2nd quarter. Millennium Management LLC now owns 686,037 shares of the company's stock valued at $5,186,000 after purchasing an additional 80,324 shares during the last quarter. Acadian Asset Management LLC lifted its position in NeuroPace by 46.0% in the second quarter. Acadian Asset Management LLC now owns 68,918 shares of the company's stock valued at $520,000 after buying an additional 21,703 shares during the last quarter. Financial Advocates Investment Management boosted its stake in NeuroPace by 50.0% during the second quarter. Financial Advocates Investment Management now owns 15,000 shares of the company's stock worth $113,000 after buying an additional 5,000 shares during the period. Rhumbline Advisers acquired a new stake in shares of NeuroPace during the second quarter valued at about $111,000. Finally, XTX Topco Ltd increased its position in shares of NeuroPace by 56.1% during the second quarter. XTX Topco Ltd now owns 24,055 shares of the company's stock valued at $182,000 after acquiring an additional 8,643 shares during the last quarter. 78.83% of the stock is currently owned by institutional investors and hedge funds.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.